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KEY PO INT S
l Pegylated-rIFN-a2a
can achieve an ORR
of 69% and 60% in ET
and PV patients,
respectively,
previously treated
with hydroxyurea.
l The presence of a
CALR mutation was
associated with
superior CR rates in ET
patients treated with
pegylated-rIFN-a2a.
Prior studies have reported high response rates with recombinant interferon-a (rIFN-a)
therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To
further define the role of rIFN-a, we investigated the outcomes of pegylated-rIFN-a2a (PEG)
therapy in ET and PV patients previously treated with hydroxyurea (HU). The Myelopro-
liferative Disorders Research Consortium (MPD-RC)-111 study was an investigator-initiated,
international, multicenter, phase 2 trial evaluating the ability of PEG therapy to induce
complete (CR) and partial (PR) hematologic responses in patientswith high-risk ET or PVwho
were either refractory or intolerant to HU. The study included 65 patients with ET and 50
patients with PV. The overall response rates (ORRs; CR/PR) at 12monthswere 69.2% (43.1%
and 26.2%) in ET patients and 60% (22% and 38%) in PV patients. CR rates were higher in
CALR-mutated ET patients (56.5% vs 28.0%; P 5 .01), compared with those in subjects
lacking aCALRmutation. Themedian absolute reduction in JAK2V617F variant allele fraction
was26% (range,284% to 47%) in patients achieving a CR vs14% (range,218% to 56%) in
patients with PR or nonresponse (NR). Therapy was associated with a significant rate of
adverse events (AEs); most were manageable, and PEG discontinuation related to AEs occurred in only 13.9% of subjects.
We conclude that PEG is an effective therapy for patients with ET or PV who were previously refractory and/or intolerant
of HU. This trial was registered at www.clinicaltrials.gov as #NCT01259856. (Blood. 2019;134(18):1498-1509)
Introduction
Polycythemia vera (PV) and essential thrombocythemia (ET) are
BCR-ABL1–negative myeloproliferative neoplasms. Both dis-
eases are characterized by a clonal myeloid proliferation with
excessive production of blood elements.1 They are characterized
by various degrees of erythrocytosis, thrombocytosis, leukocy-
tosis, systemic symptoms, and extramedullary hematopoie-
sis. The hallmarks of ET and PV include an increased risk of
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thrombohemorrhagic complications, and a variable risk of trans-
formation to myelofibrosis (MF) and/or acute myeloid leukemia
(AML).2,3
Therapeutic approaches to these diseases have predominantly
addressed the importance of thrombohemorrhagic risk mitiga-
tion with cytoreductive therapy, as well as aspirin, in the ap-
propriate patients. The study of disease-modifying agents has
been challenging, owing to several barriers, including the rel-
ative rarity of these neoplasms, the difficulty of enrolling patients
in multicenter clinical trials, different response criteria used
across trials, and the relatively indolent nature of these diseases,
thereby accentuating the need to identify clinically meaningful
surrogate end points.
Hydroxyurea (HU) is generally accepted as front-line therapy for
high-risk ET and PV patients. Because a significant number of
patients are either intolerant of HU because of hematologic or
nonhematologic toxicity or resistant because of a lack of ef-
fective cytoreduction, alternative therapeutic agents are clearly
needed.4,5 HU resistance is associated with an inferior prognosis,
increased mortality, and increased rate of transformation to more
advanced myeloproliferative neoplasm (MPNs).4 IFNs, and, more
recently, recombinant pegylated IFN-a, have been explored as
alternatives to HU. Several clinical trials have shown promising
response rates; however, these trials have also reported side effects
leading to significant rates of therapy cessation.6-21
We carried out a prospective phase 2 trial through the Myelo-
proliferative Disorders Research Consortium (MPD-RC) to in-
vestigate the response rates and toxicity profile of recombinant
pegylated IFN alfa-2a (peg-rIFN alfa-2a; Pegasys, PEG).
Patients and methods
MPD-RC 111 was an international, multicenter, phase 2, open-
label clinical trial (clinicaltrials.gov #NCT01259817) that was
conducted at participating sites in North America and Europe.
The study was approved by the institutional review boards
or ethics committees of each institution and was conducted
according to the criteria set by the Declaration of Helsinki. Each
subject signed an informed consent document before partici-
pating in the trial.
The diagnosis of ET or PV was established using criteria outlined
by the World Health Organization (WHO) 2008.22 High-risk
features included a history of thrombosis; age .60 years; a
history of bleeding (ET only); platelet counts,.15003 109/L in ET
and.10003 109/L in PV; vasomotor symptoms (erythromelalgia,
severe migraine headaches); significant or symptomatic spleno-
megaly; and the presence of diabetes or uncontrolled hyper-
tension. The patients enrolled were resistant to and/or intolerant
of HU, according to previously published criteria.23 These criteria
include failure to achieve adequate cytoreduction (platelet count,
$600 3 109/L; hematocrit [HCT], .45% or continued need for
therapeutic phlebotomy; or white blood cell [WBC] count,.103
109/L), the development of or progression of splenomegaly,
development of major thrombotic episodes ,despite the maxi-
mum tolerated dose (MTD) of HU, or development of hemato-
logic or nonhematologic toxicities at any dose of HU. The study
also included an additional group of 20 patients who had
experienced a splanchnic vein thrombosis, regardless of treat-
ment history, which was reported separately.
Patients were excluded if they had received previous therapy
for ET and PV with an agent other than HU, had had prior
therapy with IFN, or had contraindications to IFN therapy, such as
an uncontrolled autoimmune disorder, uncontrolled depression,
or severe retinal disease. The study was designed to accrue
84 patients each with ET or PV for a total of 168 patients, but
because of lack of study drug availability, the study was closed to
accrual in December 2016 after 115 patients were enrolled from
February 2012 through December 2015.
An intention-to-treat (ITT) response evaluation was performed
every 12 months. Patients who achieved at least a partial re-
sponse (PR) remained on treatment and were observed for a
maximum of 4 years. All enrolled patients were included in
response assessments. The primary end point consisted of
complete response (CR) and PR (overall response rate, ORR) at
12 months, as determined by European LeukemiaNet (ELN)
criteria,24 which define CR as correction of the platelet count to
,400 3 109/L, HCT to ,45% without phlebotomy (for PV pa-
tients only), and WBC to ,10 3 109/L; resolution of spleno-
megaly; and resolution of disease-related symptoms (defined as
microvascular disturbances, headache, and pruritus). Responses
were assessed by a blinded central review committee. Sec-
ondary end points included the evaluation of toxicity, safety, and
tolerability of PEG; the impact of PEG on key disease biomarkers;
the incidence of disease transformation; the evaluation of changes
in bone marrow (BM) histopathology, quality of life (QoL), and
patient-reported symptoms; and the assessment of major
cardiovascular events.
Patients completed a comprehensive assessment of myelo-
proliferative neoplasm (MPN)-associated symptoms (the Mye-
loproliferativeNeoplasm SymptomAssessment Form [MPN-SAF]),
an assessment of functionality and QoL (The European Orga-
nisation for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30 [EORTC QLQ-C30]), and 5 exploratory
questions to assess PEG-related side effects on a serial basis
(baseline, 3, 6, 9, 12 months).
PEG was generously provided by Roche/Genentech Pharma-
ceuticals. The drug was administered subcutaneously at a
starting dose of 45 mg weekly and titrated monthly in 45-mg
increments for response up to a maximum of 180 mg weekly.
Dose escalation occurred when the criteria for CR and dose-
limiting toxicity were not met. Subjects with a CR or PR at month
12 were eligible to continue treatment at the same dose until
loss of response, unacceptable toxicity, patient/physician de-
cision, or completion of the study period at 4 years. Subjects with
no response or stable disease at month 12 did not continue
receiving treatment.
Disease biomarkers
BM histopathology, karyotype analyses, and gene mutation
analyses were performed at baseline, after 12 and 24 months,
and at the end of study. The BM biopsies were examined by an
expert hematopathologist without knowledge of the clinical or
molecular responses. Histomorphologic remission was defined
according to ELNcriteria and the revisedELN-InternationalWorking
Group consensus criteria.25 Next-generation sequencing (NGS)
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was performed with a targeted sequencing panel designed to
capture 156 genes implicated in myeloid malignancies.26 DNA
was derived from the peripheral blood mononuclear cell frac-
tion. Samples were sequenced on the Illumina HiSeq 4000
system with an average target depth of 9923 (126 bp paired-
end reads). The raw sequence data were aligned to the GRCh37
reference genome using the BWA-MEM algorithm (v. 0.7.12-
r1039).27 Candidate substitutions and insertions and dele-
tions were called using cgpCaVEMan (v. 1.7.4) and cgpPindel
(v. 1.5.4). Candidate mutations were compared with COSMIC
(v. 81),28 ExAC (v. 03.12)29 and 1000Genomes (phase 3 release),30,31
to manually assess each variant and classify it as pathogenic,
likely pathogenic, or variant of uncertain significance (VUS). The
variants presented in this study were identified as pathogenic or
likely to be pathogenic. Copy number alterations were called
using the CNVkit algorithm (v.0.8.5).32 Normalized log-ratio plots
were assessed to identify chromosomal changes into gains and
losses.
Statistical analysis For each disease cohort, a 50%ORR achieved
during the first 12 months was considered acceptable. With the
original sample size of 84 patients in each cohort, a difference in
ORR from 35% to 50% provided 80% power (a 5 0.05). Patients
who dropped out prior to 12 months for lack of response, tol-
erability, or complications were considered nonresponders (NRs).
Baseline demographics, clinical characteristics, and baseline
mutational status were reported for ET and PV patients. Maximum
grade adverse events (AEs) were summarized, regardless of at-
tribution. Responses at 12 months were reported and ORR
(CR1PR) along with exact 95% confidence intervals (CIs) were
reported. For each cohort, an independent z test was conducted
to test the null hypothesis that the ORR was equal to 35%. Clinical
variables were examined according to clinical response using the
independent-samples Student t test or the x2 test for frequency
data. Logistic regression was used to examine the association of
CR at 12 months with patient demographic and clinical charac-
teristics. Incidence of vascular events and second cancers were
estimated using cumulative incidence. Patient-reported outcome
measurements were scored according to published scoring al-
gorithms. Within-group changes and between-group differences
over time were assessed by mixed models adjusted for age.
Analysis of covariance (ANCOVA) adjusting for baseline scores
compared 12-month score between patients with a CR vs those
with PR/NR.
Results
Patients
A total of 115 patients (ET, 65; PV, 50) participated in the study.
The median patient age was 64.0 years. The median time from
diagnosis was 37.3 months for ET and 54.8 months for PV.
Seventy-seven (67.5%) patients were classified as HU-intolerant,
and 37 (32.5%) were HU-resistant (Table 1). Prior thrombosis was
present in 32.3% of ET patients and in 22% of PV patients. Seven
(ET, 4; PV, 3) of 32 patients had an event during the year prior to
enrollment (transient ischemic attack, 2; deep venous throm-
bosis, 1, other, 4). A palpable spleen was present in 16.9% of ET
patients and in 44% of PV patients. In these patients, median
spleen length was 7.0 cm (range, 1-23) below the left costal
margin by palpation and 16.0 cm (range, 7-28 cm) by ultrasound
imaging. Despite meeting the criteria for HU intolerance or
resistance, 63.5% of patients remained on HU at the time of
enrollment.
NGS was performed on baseline samples from 110 patients for
whom baseline sequencing data were available. In total we
identified 239 mutations in 45 genes in 110 baseline samples.
Among MPN driver mutations, activating JAK2 mutations were
most frequent (72%), followed by CALR mutations (21%) and
MPL mutations (5%; Figure 1; Table 1). A median of 3 variants
were observed per baseline sample. Frequent mutations in other
known cancer genes included TET2 (17%), TP53 (9%), DNMT3A
(9%), and ASXL1 (8%) (Figure 1; supplemental Figure 1; available
on the Blood Web site). The median JAK2V617F variant allele
frequency (VAF) at baseline was 29% (1%-96%).
Baseline MPN symptoms and QoL
Of the 115 patients, 114 (ET, 64; PV, 50) completed baseline
symptom and QoL assessments. Mean MPN-SAF Total Symp-
tom Score (TSS scale, 0 [absent]-100 [worst imaginable]33) was
19.5 (SD 18.4; range, 0-95) with means of 19.0 (SD 18.1) and 20.1
(SD 19.0) for ET and PV (P5 .76), respectively, similar to reported
means of a previous cohort receiving any line of treatment (ET
mean, 18.7, SD 15.3; PV mean, 21.8, SD 16.3). The most
common baseline symptoms were fatigue (106/114, 93%) and
insomnia (74/114, 65%). The mean QLQ-C30 Global Health
Status/QoL (GHS/QoL scale, 0 [very poor]-100 [excellent]) was
71.6 (SD 20.1). Baseline TSS and GHS/QoL did not significantly
differ between ET and PV, nor among patients with different
driver mutations (TSS, 19.5 (17.0): JAK2 vs 14.9 (13.5) CALR,
P 5 .25; QoL 72.7 (20.0): JAK2 vs 68.1 (22.8) CALR, P 5 .36).
Responses
Primary end point All 115 patients were included in ITT re-
sponse assessment at 12 months. Patients removed from treat-
ment because of withdrawal of consent or significant AEs that
precluded any effective therapy were considered NRs for pur-
poses of response assessment at 12 months. Median follow-up
time was 19.6 months (range, 0.6-56.6).
In ET patients, CR and PR at 12 months were observed in 28
(43.1%) and 17 (26.2%) patients, for an ORR of 69.2% (95% CI,
56.6%-80.0%), which differed significantly from the null hy-
pothesis of 35% (z 5 5.79; P , .001). In PV patients, 11 (22%)
attained a CR and 19 (38%) a PR, for an ORR of 60% (95%
CI, 45.2%-73.6%), which also differed significantly from 35%
(z 5 3.71; P , .001; Figure 2). The best response (ORR) at any
time point was 70.8% (95% CI, 58.2%-81.4%) for ET patients and
64.0% (95%CI, 49.2%-77.1%) for PV patients; 96.2% of all clinical
responses were achieved within 12 months of treatment. At
12 months, 23 of 50 (46%) PV patients had achieved#45% HCT.
In PV patients, 27 of 50 (54%) were receiving phlebotomy at
enrollment with a median of 2.0 (range, 1-12) phlebotomies in the
prior 6 months before enrollment. In these patients, the median
number of phlebotomies was 1.0 (range, 0-6) during the first
6 months of study; 10 of 27 were phlebotomy independent
during these 6 months. At 12 months, 45 of 65 (69.2%) ET
patients had achieved a platelet count #400 3 109/L.
Response at 12 months was examined in relation to clinical
factors. Age, HU resistance vs intolerance, maximum dose of
PEG, and disease duration were not predictors of attaining CR
(Table 2). Patients with ET had higher CR rates than those with PV
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Table 1. Baseline characteristics
Characteristic ET (n 5 65) PV (n 5 50) Total (N 5 115)
Sex
Female 33 (50.8) 24 (48.0) 57 (49.6)
Male 32 (49.2) 26 (52.0) 58 (50.4)
Age .60 y* 38 (58.5) 33 (66.0) 71 (61.7)
Race
White 54 (83.1) 47 (94.0) 101 (87.8)
Black or African American 6 (9.2) 2 (4.0) 8 (7.0)
Asian 2 (3.1) 0 2 (1.7)
Not reported 3 (4.6) 1 (2.0) 4 (3.5)
ECOG performance status (grade)
0 44 (67.7) 33 (66.0) 77 (67.0)
1 21 (32.3) 16 (32.0) 37 (32.2)
2 0 (0.0) 1 (2.0) 1 (0.9)
Previous thrombosis 21 (32.3) 11 (22.0) 32 (27.8)
Previous hemorrhage 7 (10.8) 6 (12) 13 (11.2)
Splenomegaly 12 (18.5) 28 (56.0) 40 (34.8)
Disease duration in months since diagnosis, median
(range)
37.3 (0.4-291) 54.8 (0.5-394) 42.3 (0.5-394)
HU resistant 20 (31.3) 17 (34.0) 37 (32.5)
Not achieving platelet count ,600 3 109/L† 15 (75) 4 (23.5) 19 (51.4)
Progressive splenomegaly or hepatomegaly or new
splenomegaly or hepatomegaly†
2 (10) 7 (44.2) 9 (24.3)
Not achieving a HCT ,45 without phlebotomy† 2 (10) 5 (29.4) 7 (18.9)
Not achieving a WBC ,10 3 109/L† 5 (29.4) 2 (10) 7 (18.9)
Development of a major thrombotic episode† 7 (35.0) 2 (11.8) 9 (24.3)
HU intolerant 44 (68.8) 33 (66.0) 77 (67.5)
WBC , 2.5 3 109/L or hemoglobin ,11 g/dL at any
dose of HU
11 (25.0) 6 (18.2) 17 (22.1)
Having a platelet count ,100 3 109/L 1 (2.3) 3 (9.1) 4 (5.2)
Presence of leg ulcers or other unacceptable
HU-related nonhematological toxicities
37 (84.1) 25 (75.8 62 (80.5)
HU therapy discontinued 26 (40.0) 16 (32.0) 42 (36.5)
HU therapy ongoing 39 (60.0) 34 (68.0) 73 (63.5)‡
WBC (3109/L), median (range) 7.4 (2.4-55.7) 11.1 (2.3-45.3) 8.5 (2.3-55.7)
Platelets (3109/L), median (range) 609 (124-1899) 378 (15.2-1698) 485 (15.2-1899)
HCT %, median (range) 39.4 (40-53.7) 44 (27.5-55.8) 41 (40-55.8)
Driver mutations, n
JAK2V617F 31 48 —
CALR 23 — —
MPL 4 1 —
Triple negative or unavailable 8 2 —
Data are n (%), unless otherwise noted.
*Median: 64.0 y (range, 20-85).
†After 3 months of at least 2 g/d of HU or MTD of HU.
‡Median: 22.5 months (range, 1.0-153).
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(43% vs 22%; odds ratio [OR], 2.68; 95% CI, 1.17-6.15). CR rates
were higher in CALR-mutated patients than in patients without a
CALRmutation (56.5% vs 28.0%, P5 .01; OR, 3.34; 95%CI, 1.28-
8.67). Of the 11 ET and PV patients with baseline TP53 muta-
tions, only 3 achieved a CR. Of the 8 patients with the ASXL1
mutation, 3 achieved CR, 2 achieved PR, and 3 were NR.
Spleen responses Of 52 patients with a baseline spleen size
.13 cm by imaging, 17 (32.7%) had normalization (decrease
to ,13 cm on imaging) with treatment. The median absolute
change in spleen size was only 2%.
Number of vascular events Nomajor bleeding events occurred
during the study period. Cumulative incidence of major vascular
events at 1 year was 2% (95% CI, 1%-8%) and at 2 years was 5%
(95% CI, 2%-15%) and consisted of a grade 3 venous thrombo-
embolic event, grade 3 cardiovascular disease, and 2 coronary
artery occlusions: 1 grade 2 and 1 grade 3 myocardial infarction.
Evolution of disease One patient with ET transformed to AML
within 8 weeks of therapy, but the baseline BM biopsy favored a
diagnosis of prefibrotic MF rather than ET. Transformation to MF
occurred in 1 PV patient.
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Figure 1. Genomic profile of somatic mutations and copy number variants (CNVs) in baseline samples, as detected by NGS data. Each column represents a patient
(n 5 110) and each row represents a gene that is mutated in at least 2 patients (n 5 22). In the bottom of the figure, each row represents a CNV event (n 5 10). The bar plot
(top) indicates the number of somatic mutation(s) per patient, colored according to the type of the alteration. The bar plot on the right shows the number of somatic mu-
tations per gene (top) or CNV event (bottom). The frequency of mutations in the cohort is listed on the left border of the figure. The clinical response to treatment is dis-
played in the annotation bar at the lower axis of the figure according to the legend. The second annotation bar at the bottom panel denotes the classification of each patient
according to the molecular classification criteria.34
ET PV
26%
43%
*69%
38%
22%
*60%
PR CR ORR
*p < 0.001 Figure 2. Response assessment. Overall response rate at
12 months.
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BM response Seventy-four patients were evaluated for BM re-
sponse. Histopathologic remission was observed in 9 patients
(12.2%; ET, 5; PV, 4). Histopathologic remissions were associated
with a hematologic PR/CR in 8 of the 9 patients. In 7 patients, BM
fibrosis progressed to grade 21 (scale, 0-31) while they were
receiving PEG therapy, but only 1 patient met clinical criteria for
transformation to MF. The remaining patients had stable de-
grees of BM fibrosis.
Cytogenetic and molecular response Seventeen patients had
abnormal baseline karyotype, and 4 were noted to have changes
in their chromosomal abnormalities with PEG treatment (sup-
plemental Table 1). One patient with PV and a normal karyotype
at baseline developed 18 and 19. Three PV patients, all har-
boring JAK2V617F, lost part, or all, of their clonal karyotypic
abnormalities on treatment, and all 3 achieved a CR at 12months.
Analysis of JAK2V617F allele burden revealed that patients with
CR had a significantly lower VAF at baseline compared with
those who achieved NR (Figure 3A). Decreases in the JAK2V617F
VAF appeared to be greater among patients achieving a clinical
response (Figure 3B). The median absolute change in JAK2V617F
VAF was 26% (range, 284% to 47%) in patients achieving a CR vs
14% (range, 218% to 56%) in those with PR and NR (Figure 3B;
supplemental Figure 2). A similar pattern of enrichment for CR
among patients with a decreased CALR VAF was noted, but be-
cause of the small number of patients withCALRmutations (n5 21),
this finding was not statistically significant (supplemental Figure 3).
We further sought to determine whether classification of pa-
tients by a recently described molecular prognostic system for
MPNs predicted response to therapy in this cohort.34 The most
frequent classes we observed in our cohort were JAK2, CALR,
and chromatin/spliceosome-mutant groups (Figure 1). CR re-
sponses by classification systemwere 21of 41 (51.2%) patients for
heterozygous JAK2, 11 of 24 (45.8%) for the chromatin/spliceo-
some/RASmutation, 12 of 19 (63.2%) forCALR, 3 of 11 (27.3%) for
the TP53mutation, and 4 of 10 (40.0%) for the homozygous JAK2/
NFE mutation.
MPN Symptom and QoL changes QoL questionnaires were
completed by 104 (90.4%) patients (ET, 57; PV, 47) at 3 months,
92 (80%) patients (ET, 52; PV, 40) at 6 months, 81 (70.4%)
patients (ET, 47; PV, 34) at 9 months, and 74 (64.3%) patients
(ET, 45; PV, 29) at 12 months. In a mixed model, patients
experienced statistically significant improvements in MPN-
related symptoms including TSS, fatigue, dizziness, numb-
ness and tingling, andweight loss (all P, .05). However, PEG-related
side effects, such as flulike symptoms, injection site irritation,
blurry vision, and vision changes, also developed (all P , .05;
supplemental table 2; Figure 4). GHS/QoL stayed relatively
stable over time in those patients who tolerated treatment
(P 5 NS; Figure 4). Patients with a CR had significantly im-
proved TSS, GHS/QoL score, fatigue, early satiety, and itch-
ing, compared with those with a PR/NR at 12 months (all
P , .05).
Safety Seventy-two percent of patients remained on therapy for
over 12 months, with a median (range) duration of 78.5 (1-245)
weeks for ET and 82 (4-209) weeks for PV. The mean (SD) weekly
dose of PEG was 102.7 (52.3) mg for ET and 128.7 (46.4) for PV.
The causes of discontinuation of therapy are listed in Table 3.
The 2 most common reasons were study closure (30.4%) and
completion of the planned 4-year follow-up (26.1%). Discon-
tinuation of PEG because of AEs occurred in 13.9% of patients.
Cumulative incidence of a second cancer (excluding nonmelanoma
skin cancers) at 2 years was 4% (95% CI, 1%-10%). These
consisted of lung adenocarcinoma (PV, 2; ET, 0), spindle cell
sarcoma (ET, 1) and melanoma (PV, 1). Four patients dis-
continued treatment because of secondary cancer (1 each with
lung adenocarcinoma, melanoma, spindle cell sarcoma, and
preexisting renal cell cancer).
All patients (N5 114) who received PEGwere evaluated for AEs.
One ET patient withdrew from the study before receiving treat-
ment. AEs of any grade, regardless of attribution, were reported
in 90.4% of patients. Grade $3 AEs, regardless of attribution
occurred in 50 patients (43.8%); those that occurred in .10% in
Table 2. Clinical factors and association with CR at
12 months
Risk factor
Events/patients,
n (%) OR (95% CI)
Age (continuous) — 1.02 (0.99-1.05)
Disease type
PV 11/50 (22) 2.68 (1.17-6.15)
ET 28/65 (43) —
Gender
Male 20/57 (35) 0.90 (0.42-1.95)
Female 19/58 (33) —
HU group
Resistant 10/37 (27) 1.54 (0.65-3.65)
Intolerable 28/77 (36) —
Prior thrombosis
(disease-related)
Yes 10/32 (31) 1.18 (0.49-2.83)
No 29/83 (35) —
Disease duration
(continuous)
— 0.99 (0.98-1.00)
Maximum dose PEG
received, mg/wk
45 8/26 (31) 1.39 (0.47-4.11)
90 13/34 (38) 1.39 (0.41-4.65)
135 8/21 (38) 0.98 (0.32-2.99)
180 10/33 (30) —
ECOG performance
status, grade
0 26/77 (34) 1.02 (0.45-2.32)
1/2 13/38 (34) —
CALR mutation
No 23/82 (28) 3.34 (1.28-8.67)
Yes 13/23 (56) —
JAK2 mutation
No 14/26 (54) 0.33 (0.13-0.83)
Yes 22/79 (28) —
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either cohort regardless of attribution are shown in Table 4. The
most common hematologic and nonhematologic AEs listed in
Table 4. No deaths occurred in patients during treatment, but 3
deaths occurred in patients who had been taken off study.
Reasons for discontinuation of the study in these 3 patients
were substance abuse, adenocarcinoma of the lung, and the
patient’s decision.
Discussion
This study represents the largest global effort to date to in-
vestigate the role of PEG in patients with high-risk ET or PV
refractory to or intolerant of HU therapy. PEGwas shown to be an
effective therapeutic option to treat such patients inducing an
ORR at 12 months in 69.2% and 60% of ET and PV patients,
respectively. CR rates of 43.1% and 22% in ET and PV, re-
spectively, in this study were lower than those in prior reports
(Table 5),10,15,18-21 whichmay be explained by the broad inclusion
criteria, ITT design, and international accrual. In addition, pa-
tients enrolled in this study had higher risk features, such as
advanced age, prolonged disease duration, and a high preva-
lence of splenomegaly (Table 5). In our study, we used stringent
response criteria that incorporated hematologic variables,
spleen size, and symptom responses, which were evaluated by
a blinded central review committee. We did not identify any
predictors of clinical response or observe a relationship between
the dose of PEG administered and the degree of clinical
response.
B
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-60%
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CR PR NR
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Figure 3. Changes in mutant JAK2 (p.V617F) VAF over time. (A) VAF in evaluable samples at baseline, month 12, and end of study. The added P-values highlight a significant
difference in median JAK2V617F VAF between CR and NR groups in baseline samples (Wilcoxon test; P 5 9.51e-03). (B) JAK2V617F VAF waterfall plot. The y-axis indicates
the absolute change of JAK2V617F VAF from baseline to last sample. Each bar represents a patient, highlighted by the best clinical response (as described in the color key).
Analysis of the number of patients with increased and decreased VAF between groups indicates that the chance of achieving CR is 15 times higher for patients with a reduced
JAK2V617F allele burden (Fisher’s exact test; P 5 9.071e-06; OR, 15).
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PEG therapy resulted in an overall improvement in MPN-related
symptoms, but the toxicities associated with PEG may have
abrogated some of those benefits. Despite the mixed symptom
picture, PEG did not reduce the QoL of patients who were able
to tolerate treatment. BM responses and deep molecular re-
sponses were infrequent which might be attributed to the rel-
atively short follow-up. The effect of achieving a molecular
remission with PEG on survival and clinical outcomes has yet to
be determined. In addition, there has been significant hetero-
geneity in the sensitivity of the assays used tomeasuremolecular
responses among different reports.
Response rates according to driver mutational status were
evaluated, and only the presence of the CALR mutation was
2
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Figure 4. Mean changes from baseline during treatment.Negative changes indicate improvement. *MPN-SAF TSS and EORTCQLQ-C30 GHS/QoL transformed to a 0 to 10
scale, where 10 represents the worst outcome, for consistency with other displayed items.
Table 3. Reasons for discontinuation of treatment
ET (n 5 65) PV (n 5 50) Total (N 5 115)
Study closure 22 (33.8) 13 (26.0) 35 (30.4)
Treatment of 48 mo completed 18 (27.7) 12 (24.0) 30 (26.1)
AE 7 (10.8) 9 (18.0) 16 (13.9)
Disease progression 7 (10.8) 6 (12.0) 13 (11.3)
Refused further treatment 7 (10.8) 5 (10.0) 12 (10.4)
Developed other primary solid tumors* 2 (3.1) 2 (4.0) 4 (3.5)
Removed to receive nonprotocol therapy? 2 (3.1) 0 (0.0) 2 (1.7)
Noncompliance 0 (0.0) 1 (2.0) 1 (0.9)
Other† 0 (0.0) 2 (4.0) 2 (1.7)
Data are n (%).
*Two ET patients discontinued treatment due to spindle cell sarcoma and preexisting renal cell cancer, and 2 PV patients developed melanoma and lung adenocarcinoma and discontinued
treatment.
†Investigator decision (n 5 1); patient perceived inefficacy of treatment (n 5 1).
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associated with a superior clinical, but not molecular, response.
It is notable that mutations in TP53 and ASXL1 were among
the most frequently co-occurring mutations in this cohort, sug-
gesting that patients with genomically unfavorable disease were
included in this study. A significant difference in the baseline
JAK2V617F VAF was observed between patients achieving a CR
and thosewithNR, suggesting that therapeutic efficacy of PEGmay
be greater in a molecularly defined subgroup of patients. A re-
duction in the JAK2V617F VAF over time was observed in patients
with a CR, as compared with an NR, which links a reduction in VAF
to clinical response. In additional, 3 patients with PV had complete
or partial normalization of abnormal baseline karyotype while on
PEG therapy, which was in concordance with their clinical CR.
Thrombotic events and evolution to MF or AML continued to
occur during the treatment period. This observation reaffirms
the findings of a recent prospective single-institution trial of
PEG in patients with ET or PV, in which the observed rate of
transformation toMF and AMLwas similar in treated patients and
historical controls matched for disease duration, prior therapy,
and molecular features.10 In addition, unprovoked thrombosis
was observed at a rate of 1.22 per person-year.
AEs, particularly those of grades 3 and 4, were detected in slightly
more than one third of the subjects. Many of these events were
consistent with the known effects of PEG. Given the prospective
nature of our study, the higher rate of AEs reported here is
expected. Treatment-emergent AEs, a rate that has been variable
in other reports, led to discontinuation of therapy in only 13.9% of
subjects (Table 5). This low discontinuation rate may be attribut-
able to the dosing schedule of PEG, starting with a low dose and
allowing for gradual dose escalation.
Recently, the JAK1/JAK 2 inhibitor ruxolitinib was evaluated as a
therapeutic agent to treat patients with ET or PV who were
resistant to, or intolerant of, HU therapy. The MAJIC-ET trial35
Table 4. AEs occurring in >10% in either disease strata, regardless of attribution
ET (n 5 64) PV (n 5 50)
All grades Grade 31 All grades Grade 31
Hematologic
Anemia 16 (25.0) 4 (6.3) 8 (16.0) —
Leukopenia 13 (20.3) 1 (1.6) 11 (22.0) 2 (4.0)
Lymphocytopenia 9 (14.1) 1 (1.6) 9 (18.0) 3 (6.0)
Neutropenia 9 (14.1) 5 (7.8) 4 (8.0) 2 (4.0)
Thrombocytopenia 6 (9.4) — 9 (18.0) —
Nonhematologic
Abdominal pain 7 (10.9) — 2 (4.0) —
Alanine aminotransferase 6 (9.4) 2 (3.1) 5 (10.0) —
Arthralgia 9 (14.1) — 5 (10.0) 2 (4.0)
Bone pain 7 (10.9) — 4 (8.0) —
Constipation 9 (14.1) — 7 (14.0) —
Cough 11 (17.2) — 4 (8.0) —
Cramp 10 (15.6) — 3 (6.0) —
Creatinine increased 1 (1.6) — 6 (12) —
Depression 8 (12.5) — 4 (8.0) 1 (2.0)
Diarrhea 9 (14.1) 1 (1.6) 20 (40.0) —
Dizziness 12 (18.8) — 7 (14.0) —
Dyspnea 10 (15.6) 1 (1.6) 5 (10.0) 1 (2.0)
Edema 9 (14.1) — 9 (18.0) —
Fatigue 28 (43.8) 1 (1.6) 20 (40.0) —
Flulike symptoms 11 (17.2) 1 (1.6) 9 (18.0) —
Headache 20 (31.3) 2 (3.1) 13 (26.0) 1 (2.0)
Hyperuricemia 4 (6.3) — 9 (18.0) —
Injection site reaction 13 (20.3) — 17 (34.0) —
Insomnia 4 (6.3) — 8 (16) —
Lightheadedness 8 (12.5) — 1 (2.0) —
Myalgia 10 (15.6) — 7 (14.0) —
Nausea 15 (23.4) — 12 (24.0) —
Pain 12 (18.8) 1 (1.6) 15 (30.0) 1 (2.0)
Pruritus 15 (23.4) — 11 (22.0) —
Rash 7 (10.9) 1 (1.6) 5 (10.0) 1 (2.0)
Upper respiratory infection 8 (12.5) — 4 (8.0) —
Urinary tract infection 7 (10.9) 1 (1.6) 5 (10.0) —
Vomiting 2 (3.1) — 8 (16.0) —
All data are n (%).
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reported that ruxolitinib was not superior to best available
therapies (BATs). It is noteworthy that, given the lack of alter-
native therapies, the most common BAT included HU (71.1%),
anagrelide (48.1%), and IFN (40.4%). Although these authors
used ELN response criteria for CR, resolution of disease-related
symptoms was not included, and over 70% of patients continued
to receive HU as BAT, raising doubt about true resistance or
intolerance. The use of modified ELN criteria in the MAJIC-ET
trial may account for the higher CR rate (44.2%) reported with
ruxolitinib than that observed in this trial (35.3%). In contrast, the
RESPONSE 1 trial36 compared the ability of ruxolitinib and BAT
to achieve HCT control and a 35% reduction in splenomegaly in
an advanced group of PV patients who were resistant to or in-
tolerant of HU therapy and had palpable splenomegaly. This
composite end point was achieved in 20.9% of patients receiving
ruxolitinib therapy and 0.9% of patients receiving BAT. Because
ELN response criteria were not used in RESPONSE 1, it is difficult
to compare these results to those that we observed with PEG
therapy, although theCR rates are comparable. Using reduction of
splenomegaly as a criterion for clinical response is of dubious
value in PV, because only 44% of PV patients in our trial had
palpable splenomegaly, and they were rarely symptomatic. This
concern regarding trial design led to the RESPONSE 2 trial, in
which ruxolitinib therapy in PV patients without splenomegaly was
compared with BAT in patients whowere phlebotomy dependent
and resistant to or intolerant of HU therapy. Again, phlebotomy
control, rather than ELN criteria, was used to define the ORR and
49% of the patients in the BAT arm continued to receive HU
therapy. HCT control was achieved in 62% of patients receiving
ruxolitinib and 19% of patients receiving BAT. Since the criteria
used to define CR were clearly different in the RESPONSE 1 and
2 trials than those used in MPD-RC 111 trial, it is not possible to
evaluate whether PEG or ruxolitinib is the optimal treatment
choice for ET and PV patients resistant to or intolerant of HU. The
results of this study are of particular significance in light of the
recent European Commission approval of ropeginterferon for the
treatment of patients with PV based on the PROUD-PV trial
(NCT01949805).
In conclusion, in the setting of HU resistance or intolerance, PEG
has demonstrated activity in high-risk ET and PV patients and
should be considered an effective therapeutic choice. Proper
patient selection, gradual dose escalation, and prompt evaluation
andmanagement of AEs can increase the efficacy and tolerability
of PEG in ET and PV patients. Whether PEG or ruxolitinib or a
combination of the 2 drugs is the more effective therapy for
PV and ET patients clearly requires additional clinical trials
using carefully defined patient populations and uniform re-
sponse criteria.
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